LCE Funding

LCE is a branch of the Lymphoma Coalition, with an autonomous budget and a dedicated bank account. LCE’s relationships with its sponsors and supporters are regulated by LC policies on Funding Agreements and Transparency. LC and LCE accounts are reviewed on a yearly basis by a statutory auditor. 

In the financial years ending 30 April 2017 and 2018, LCE has received funding from the following companies:

  • AbbVie
  • Amgen
  • Bristol-Myers Squibb
  • Celgene
  • Gilead
  • Janssen
  • Pfizer
  • Servier
  • Takeda

For further information on LCE’s funding sources and activities click on the links below:

LCE Funding from Healthcare and Pharmaceutical Industry Sources 2016/17

LCE Funding from Healthcare and Pharmaceutical Industry Sources 2017/18

Lymphoma Coalition Financial Information (2017)

Lymphoma Coalition 2017 AGM Report

 

Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

IN THE NODE

Updates

 

The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.